BRIEF-GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged

AnaptysBio, Inc.
GlaxoSmithKline plc Sponsored ADR

AnaptysBio, Inc.

ANAB

0.00

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

April 27 (Reuters) - GSK plc GSK.L:

  • GSK PLC - TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION

  • GSK PLC - TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION

  • GSK - TESARO'S REMAINING CLAIM FOR DECLARATORY JUDGMENT AGAINST ANAPTYSBIO UNCHANGED

  • GSK - ANAPTYSBIO SEEKS TO REVOKE TESARO'S LICENCE FOR DOSTARLIMAB

  • GSK: GSK AND TESARO FIRMLY OF VIEW THAT ALLEGATIONS ARE ENTIRELY WITHOUT MERIT AND REMAIN FOCUSED ON PURSUING THAT CLAIM AT TRIAL

Source text: ID:nRSa9962Ba

Further company coverage: GSK.L


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.